Skip to main content

Effect of Probiotic Lactobacillus salivarius UBL S22 and Prebiotic Fructo-oligosaccharide on Serum Lipids, Inflammatory Markers, Insulin Sensitivity, and Gut Bacteria in Healthy Young Volunteers

  • 2014-10-20
  • Journal of Cardiovascular Pharmacology and Therapeutics 20(3)
    • H. Rajkumar
    • Manoj Kumar
    • Nilita Das
    • Subramanian Hari Subbish Kumar
    • Hanumanth R. Challa
    • R. Nagpal

Abstract

This study investigated the effect of 6-week supplementation of a probiotic strain Lactobacillus salivarius UBL S22 with or without prebiotic fructo-oligosaccharide (FOS) on serum lipid profiles, immune responses, insulin sensitivity, and gut lactobacilli in 45 healthy young individuals. The patients were divided into 3 groups (15/group), that is, placebo, probiotic, and synbiotic. After 6 weeks, a significant reduction (P < .05) in total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides and increase in high-density lipoprotein cholesterol was observed in the probiotic as well as in the synbiotic group when compared to placebo; however, the results of total cholesterol and LDL-cholesterol were more pronounced in the synbiotic group. Similarly, when compared to the placebo group, the serum concentrations of inflammatory markers such as high sensitivity C-reactive protein, interleukin (IL) 6, IL-1β, and tumor necrosis factor α were significantly (P < .05) reduced in both the experimental groups, but again the reduction in the synbiotic group was more pronounced. Also, an increase (P < .05) in the fecal counts of total lactobacilli and a decrease (P < .05) in coliforms and Escherichia coli was observed in both the experimental groups after 6 weeks of ingestion. Overall, the combination of L salivarius with FOS was observed to be more beneficial than L salivarius alone, thereby advocating that such synbiotic combinations could be therapeutically exploited for improved health and quality of life.

Keywords: Lactobacillus salivarius; fructo-oligosaccharides; inflammation; insulin resistance; prebiotics; probiotics; synbiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus SalivariusImproved Insulin SensitivityBeneficial
Moderate
Lactobacillus SalivariusImproved Lipid ProfileBeneficial
Moderate
Lactobacillus SalivariusIncreased Fecal LactobacilliBeneficial
Moderate
Lactobacillus SalivariusReduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius BLIS K12Increased Fecal LactobacilliBeneficial
Moderate
Lactobacillus salivarius BLIS K12Increased HDL Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius BLIS K12Reduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius BLIS K12Reduced LDL CholesterolBeneficial
Moderate
Lactobacillus salivarius BLIS K12Reduced Total Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius BLIS K12Reduced Triglyceride LevelsBeneficial
Moderate
Lactobacillus salivarius CRL 1328Improved Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus salivarius CRL 1328Improved Insulin SensitivityBeneficial
Moderate
Lactobacillus salivarius CRL 1328Improved Serum LipidsBeneficial
Moderate
Lactobacillus salivarius CRL 1328Reduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius HA-118Improved Gut Microbiome CompositionBeneficial
Moderate
Lactobacillus salivarius HA-118Improved Serum LipidsBeneficial
Moderate
Lactobacillus salivarius HA-118Reduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius SD-5208Improved Insulin SensitivityBeneficial
Moderate
Lactobacillus salivarius SD-5208Increased Gut Lactobacilli LevelsBeneficial
Moderate
Lactobacillus salivarius SD-5208Increased HDL Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius SD-5208Reduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius SD-5208Reduced LDL CholesterolBeneficial
Moderate
Lactobacillus salivarius SD-5208Reduced Total Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius SD-5208Reduced Triglyceride LevelsBeneficial
Moderate
Lactobacillus salivarius SD-5851Improved Gut Microbiome CompositionBeneficial
Moderate
Lactobacillus salivarius SD-5851Improved Lipid ProfileBeneficial
Moderate
Lactobacillus salivarius SD-5851Reduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius UALb-07Improved Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus salivarius UALb-07Improved Lipid ProfileBeneficial
Moderate
Lactobacillus salivarius UALb-07Reduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius UALs07Improved Gut Lactobacilli CountBeneficial
Large
Lactobacillus salivarius UALs07Increased HDL Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius UALs07Reduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius UALs07Reduced LDL CholesterolBeneficial
Moderate
Lactobacillus salivarius UALs07Reduced Total Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius UALs07Reduced Triglyceride LevelsBeneficial
Moderate
Lactobacillus salivarius UALs07 UASImproved Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus salivarius UALs07 UASImproved Lipid ProfileBeneficial
Moderate
Lactobacillus salivarius UALs07 UASReduced Inflammatory ResponseBeneficial
Moderate
Lactobacillus salivarius VPro 15Increased Gut Lactobacilli CountsBeneficial
Moderate
Lactobacillus salivarius VPro 15Increased HDL Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius VPro 15Reduced LDL CholesterolBeneficial
Moderate
Lactobacillus salivarius VPro 15Reduced Total Cholesterol LevelsBeneficial
Moderate
Lactobacillus salivarius VPro 15Reduced Triglyceride LevelsBeneficial
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.